All Articles

Mineralys Therapeutics' Lorundrostat shows promise in reducing heart failure risk, a breakthrough for millions struggling with uncontrolled hypertension.

With its new ISED-certified Private 5G portfolio for Canada's NCL band, Ontario's BLiNQ Networks is poised to drive industrial automation and smart city growth.

A novel partnership aims to power a Newfoundland nickel mine with hydrogen generated from the mine's own rock, a first-of-its-kind model for green industry.

VENU's $50M sale-leaseback fuels a rapid expansion. But is its innovative financial model a new blueprint for growth or a high-stakes bet on the future?

New trial data shows Sequel Med Tech's twiist™ AID system could bring much-needed simplicity and safety to millions with insulin-treated type 2 diabetes.

Phenomenex, a Danaher company, launches its Luna Omega HILIC columns, aiming to simplify complex analysis in pharma, food safety, and diagnostics.

Kymera Therapeutics' new lupus data isn't just about a drug. It's about a new strategy: erasing disease-causing proteins to build resilient value.

Global outdoor brand BLACKYAK moves beyond declarations, taking its climate summit to the Himalayan frontlines to launch a concrete action plan with local communities.

CAMIN’s appointment of Tom Parks as CFO is more than a personnel change. It's a clear signal of a strategic bet on technology to redefine a critical global industry.

A key hospitality tech acquisition signals a major shift from fixing Wi-Fi problems to proactively validating the entire network, a move with broad implications.

Medtronic veteran Jesse Litwak joins ProVerum, a move signaling the BPH innovator is shifting from R&D to aggressive commercial scale-up with its new ProVee tech.

Beyond a simple plea for donations, Héma-Québec is executing a sophisticated strategic campaign to secure Quebec's most vital, and volatile, supply chain.

As the Pentagon scrambles for battle-tested autonomous weapons, a new partnership promises to deliver. But is fast-tracking foreign tech the answer or a risky bet?

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

Calpine's new 25MW geothermal expansion at The Geysers provides baseload power for 25,000 homes, boosting California's grid and cementing Constellation's strategy.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

Beyond the blowout earnings, Optical Cable Corp's Q2 results reveal a playbook for thriving in the digital infrastructure boom. Here's the strategic rationale.

Ares Capital, a giant in middle-market finance, just opened a new $1B funding spigot. Is this a blueprint for the BDC industry or a sign of cheaper capital for American businesses?

Beyond the gridlock in Meriden lies a story of strategic ambition. A look at how Parsons' engineering and a massive state investment aim to redefine a vital corridor.

How new high-resolution analysis at Canadian GoldCamps' flagship project is de-risking a complex deposit and revealing its true high-grade potential.